英硅智能(03696)午后持续上扬13.73% 药物靶点发现统一AI框架取得新进展

金吾财讯04-20

金吾财讯 | 英硅智能(03696)午后涨幅较早盘有所回落，截至发稿，报69.2港元，涨13.73%，成交额4.75亿港元。今日早盘，其涨幅一度拉升至17.76%。

消息面上，英硅智能新近宣布，其用于药物靶点发现的统一AI框架取得了新进展：公司已将此前推出的靶点识别专业版(TargetIdentificationPro，TargetPro)与靶点识别基准评测体系(TargetIdentificationBenchmark，TargetBench1.0)整合为一套经验证的系统，旨在进一步提升早期药物研发的准确性、可靠性与可扩展性，该框架在基准评测与真实世界的靶点发现工作流中均展现出卓越结果，进一步展现了其作为AI驱动靶点识别“标准化底座”的价值。

此外，英硅智能还与泰格医药签署了战略合作协议，双方将围绕创新药产品的临床研究开展长期战略合作，合作服务范围全面覆盖临床监查、数据管理与统计分析、医学事务、药物警戒、注册事务等核心环节。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2628671948?lang=zh_CN&edition=full","thumbnail":"https://static.szfiu.com/news/20241108/ODBhOTU0MzI3NjMwOTM5MjE=.jpg","is_english":false,"pubTime":"2026-04-20 13:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2628671948","market":"fut","top_or_hot":-1,"title":"英硅智能(03696)午后持续上扬13.73% 药物靶点发现统一AI框架取得新进展","media":"金吾财讯","content":"<html><body><p>金吾财讯 | 英硅智能(03696)午后涨幅较早盘有所回落，截至发稿，报69.2港元，涨13.73%，成交额4.75亿港元。今日早盘，其涨幅一度拉升至17.76%。</p><p>消息面上，英硅智能新近宣布，其用于药物靶点发现的统一AI框架取得了新进展：公司已将此前推出的靶点识别专业版(TargetIdentificationPro，TargetPro)与靶点识别基准评测体系(TargetIdentificationBenchmark，TargetBench1.0)整合为一套经验证的系统，旨在进一步提升早期药物研发的准确性、可靠性与可扩展性，该框架在基准评测与真实世界的靶点发现工作流中均展现出卓越结果，进一步展现了其作为AI驱动靶点识别“标准化底座”的价值。</p><p>此外，英硅智能还与<a href=\"https://laohu8.com/S/300347\">泰格医药</a>签署了战略合作协议，双方将围绕创新药产品的临床研究开展长期战略合作，合作服务范围全面覆盖临床监查、数据管理与统计分析、医学事务、药物警戒、注册事务等核心环节。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>英硅智能(03696)午后持续上扬13.73% 药物靶点发现统一AI框架取得新进展</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n英硅智能(03696)午后持续上扬13.73% 药物靶点发现统一AI框架取得新进展\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-20 13:29 北京时间&nbsp;&nbsp;&nbsp;<a href=1979388><strong>金吾财讯</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>金吾财讯 | 英硅智能(03696)午后涨幅较早盘有所回落，截至发稿，报69.2港元，涨13.73%，成交额4.75亿港元。今日早盘，其涨幅一度拉升至17.76%。消息面上，英硅智能新近宣布，其用于药物靶点发现的统一AI框架取得了新进展：公司已将此前推出的靶点识别专业版(TargetIdentificationPro，TargetPro)与靶点识别基准评测体系(...</p>\n\n<a href=\"1979388\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CHAT","symbol_name":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","start_time":0,"source_url":"1979388","article_id":"2628671948","we_media_id":"1086022552","thumbnails":["https://static.szfiu.com/news/20241108/ODBhOTU0MzI3NjMwOTM5MjE=.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2628671948","pubTimestamp":1776662998,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"金吾财讯","introduction":"「金吾财讯」以精准用户需求为切入点，打造一站式港美股投资细分领域品牌。依托战略合作伙伴凤凰网财经，将港美股内容传播到全球华人圈。","home_visible":1,"id":"1086022552","head_image":"https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c"},"summary":"金吾财讯 | 英硅智能 午后涨幅较早盘有所回落，截至发稿，报69.2港元，涨13.73%，成交额4.75亿港元。今日早盘，其涨幅一度拉升至17.76%。此外，英硅智能还与泰格医药签署了战略合作协议，双方将围绕创新药产品的临床研究开展长期战略合作，合作服务范围全面覆盖临床监查、数据管理与统计分析、医学事务、药物警戒、注册事务等核心环节。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","ARTY":"ISHARES FUTURE AI & TECH ETF","AIPO":"Defiance AI and Power Infrastructure ETF","AGIX":"通用人工智能 ETF-AGIX","03696":"英矽智能","BK1141":"生命科学工具和服务"},"translate_title":"Yingsi Intelligent (03696) continued to rise by 13.73% in the afternoon, and the unified AI framework for drug target discovery made new progress","themeId":"f802e45762ab994d52e03d57a8ebb996","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1.5,"CHAT":1.5,"ARTY":1.5,"AGIX":1.5,"AIPO":1.5},"content_text":"金吾财讯 | 英硅智能(03696)午后涨幅较早盘有所回落，截至发稿，报69.2港元，涨13.73%，成交额4.75亿港元。今日早盘，其涨幅一度拉升至17.76%。消息面上，英硅智能新近宣布，其用于药物靶点发现的统一AI框架取得了新进展：公司已将此前推出的靶点识别专业版(TargetIdentificationPro，TargetPro)与靶点识别基准评测体系(TargetIdentificationBenchmark，TargetBench1.0)整合为一套经验证的系统，旨在进一步提升早期药物研发的准确性、可靠性与可扩展性，该框架在基准评测与真实世界的靶点发现工作流中均展现出卓越结果，进一步展现了其作为AI驱动靶点识别“标准化底座”的价值。此外，英硅智能还与泰格医药签署了战略合作协议，双方将围绕创新药产品的临床研究开展长期战略合作，合作服务范围全面覆盖临床监查、数据管理与统计分析、医学事务、药物警戒、注册事务等核心环节。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2628671948","isCrawlerRequest":true}